epirubicin / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 217 Diseases   226 Trials   226 Trials   3828 News 


«12...1011121314151617181920...4950»
  • ||||||||||  epirubicin / Generic mfg.
    Cardiovascular risk assessed by aptamer-based proteomics is increased in early breast cancer (E-Poster Website) -  Mar 9, 2022 - Abstract #AACR2022AACR_6637;    
    Using a novel CVD risk proteomics model, we observed that (1) The CVD risk of patients with early breast cancer is increased compared to age-, sex- and risk factor-matched individuals from the general population; (2) CVD risk increases during adjuvant epirubicin-containing chemotherapy, and (3) after completed adjuvant cancer therapy CVD risk returns to pre-chemotherapy level. Use of the CVD risk score may represent a novel tool to identify and monitor cancer patients who may benefit from preventive cardioprotective therapy.
  • ||||||||||  Development of novel, non-toxic rifamycins that reverse drug resistance (Section 25) -  Mar 9, 2022 - Abstract #AACR2022AACR_2679;    
    RTI-79 works by dramatically increasing intracellular superoxide through redox cycling, triggers UPR, and downregulates Nrf-2 activity. Thus, RTI-79 increases oxidative stress through the squelching of Nrf-2’s ability to respond to chemotherapeutic stress.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    AMPA-receptor encephalitis in a patient with metastatic breast cancer receiving palbociclib (Poster Hall) -  Mar 6, 2022 - Abstract #AAN2022AAN_2625;    
    She first developed breast cancer in 2008 (ER+/PR+/HER2+), was treated with lumpectomy, radiation, chemotherapy (docetaxel, carboplatin, epirubicin, cyclophosphamide, traztuzumab) and hormonal therapy with no evidence of disease from 2009-2021. AMPAR encephalitis has been well-described as a paraneoplastic syndrome associated with breast (among other) cancers.3 Of interest in our patient’s case, her neurologic symptoms developed while her cancer was responding to chemotherapy, whereas most paraneoplastic syndromes are described in the setting of tumor progression or recurrence.4 On the other hand, ICI-AIE typically occurs within the first 3 months of therapy and is more likely to occur when the cancer is responding to therapy, consistent with our patient’s presentation.1,5 We report this case to highlight a potential association between palbociclib and ICI-AIE so other providers may consider it on the differential in a patient with new-onset neurologic symptoms while on this therapy.
  • ||||||||||  docetaxel / Generic mfg., epirubicin / Generic mfg.
    Clinical, Journal, FDG PET:  18F-FDG PET/CT in a Patient With Matrix-Producing Carcinoma of the Breast. (Pubmed Central) -  Mar 5, 2022   
    The tumor size slightly decreased after 6 cycles of neoadjuvant chemotherapy with docetaxel and epirubicin. The left breast was entirely resected subsequently, and the matrix-producing carcinoma of the breast was ultimately diagnosed.
  • ||||||||||  epirubicin / Generic mfg.
    Trial initiation date:  EPOS-1: Epirubicin for the Treatment of Sepsis & Septic Shock (clinicaltrials.gov) -  Feb 28, 2022   
    P2,  N=45, Not yet recruiting, 
    These findings suggest the possible value of blood biomarkers in the selection of individual treatments in the clinical setting. Initiation date: Sep 2021 --> Apr 2022
  • ||||||||||  epirubicin / Generic mfg.
    Trial initiation date:  Comparison of the Efficacy and Safety of Continuous and Single-Dose Intravesical Epirubicin Instillation (clinicaltrials.gov) -  Feb 24, 2022   
    P=N/A,  N=100, Not yet recruiting, 
    Finally, the change in the expression pattern of anti-apoptotic, pro-apoptotic, and autophagy protein markers was monitored by liquid-chromatography tandem-mass-spectrometry after exposure of MCF-7 to the EPI-loaded hydrogels. Initiation date: Dec 2021 --> Jun 2022
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Journal:  Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. (Pubmed Central) -  Feb 19, 2022   
    P3
    In patients with early triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab after surgery, resulted in significantly longer event-free survival than neoadjuvant chemotherapy alone. (Funded by Merck Sharp and Dohme, a subsidiary of Merck; KEYNOTE-522 ClinicalTrials.gov number, NCT03036488.).
  • ||||||||||  Enrollment open:  TARMAC: MicroRNA Profiles in Triple Negative Breast Cancer (clinicaltrials.gov) -  Feb 18, 2022   
    P2,  N=42, Recruiting, 
    (Funded by Merck Sharp and Dohme, a subsidiary of Merck; KEYNOTE-522 ClinicalTrials.gov number, NCT03036488.). Not yet recruiting --> Recruiting
  • ||||||||||  epirubicin / Generic mfg.
    Review, Journal:  Non-cytomembrane PD-L1: an atypical target for cancer. (Pubmed Central) -  Feb 10, 2022   
    In this review, we summarize the four atypical localizations of PD-L1 with a focus on their novel functions, such as gene transcription regulation, therapeutic efficacy prediction, and resistance to various cancer therapies. Additionally, we highlight that non-cytomembrane PD-L1s are of significant cancer diagnostic value and are promising therapeutic targets to treat cancer.
  • ||||||||||  cisplatin / Generic mfg., epirubicin / Generic mfg.
    Retrospective data, Journal:  Comparison of first line chemotherapy regimens for advanced soft tissue sarcoma: a network meta-analysis. (Pubmed Central) -  Feb 4, 2022   
    No regimen was superior to doxorubicin with significant statistical difference in terms of PFS and ORR, even aldoxorubicin behaved better than doxorubicin in the network analysis. Collectively, doxorubicin still can be selected preferentially for the first line chemotherapy for patients.
  • ||||||||||  epirubicin / Generic mfg.
    Clinical, Journal:  Rechallenge of anti-PD-1/PD-L1 antibody showed a good response to metastatic breast cancer: a case report. (Pubmed Central) -  Feb 3, 2022   
    With subsequent eribulin, the overall best response was progressive disease, and curative surgical resection was performed...Based on the microsatellite instability-high status, pembrolizumab was administered and showed a good response. The patient has been treated with pembrolizumab, maintaining partial response, for over 9 months, which suggests the benefit of immune checkpoint inhibitors rechallenge in breast cancer.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Trial completion, Phase classification, Trial completion date, Trial primary completion date:  LANCET: Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer (clinicaltrials.gov) -  Feb 2, 2022   
    P2,  N=31, Completed, 
    The patient has been treated with pembrolizumab, maintaining partial response, for over 9 months, which suggests the benefit of immune checkpoint inhibitors rechallenge in breast cancer. Not yet recruiting --> Completed | Phase classification: P1b --> P2 | Trial completion date: Dec 2019 --> Dec 2021 | Trial primary completion date: Dec 2019 --> Oct 2021
  • ||||||||||  cisplatin / Generic mfg., epirubicin / Generic mfg.
    Journal:  CRSP8 promotes thyroid cancer progression by antagonizing IKKα-induced cell differentiation. (Pubmed Central) -  Jan 27, 2022   
    Furthermore, we found that CRSP8 regulated the sensitivity of thyroid cancer cells to chemotherapeutics, including cisplatin and epirubicin. Collectively, our results demonstrated that CRSP8 functioned as a modulator of IKKα signaling and a suppressor of thyroid cancer differentiation, suggesting a potential therapeutic strategy for ATC by targeting CRSP8/IKKα pathway.
  • ||||||||||  imatinib / Generic mfg., cisplatin / Generic mfg., epirubicin / Generic mfg.
    Review, Journal:  Aberrant Expression of miR-1301 in Human Cancer. (Pubmed Central) -  Jan 26, 2022   
    In addition, miR-1301 is related to the anti-tumor effect of epirubicin on osteosarcoma and imatinib on chronic myeloid leukemia(CML) and can enhance the cisplatin sensitivity of ovarian cancer. This work systematically summarizes the abnormal expression and prognostic value of miR-1301 in a variety of cancers, depicts the miR-1301-related signaling pathways and ceRNA network, and provides potential clues for future miR-1301 research.
  • ||||||||||  paclitaxel / Generic mfg., epirubicin / Generic mfg.
    Clinical, Journal, BRCA Biomarker, PARP Biomarker:  A Case of Metastatic Breast Cancer with BRCA1 Mutation after Breast Reconstruction and Pregnancy (Pubmed Central) -  Jan 21, 2022   
    Concentrated glycerin and fructose, steroid administration, and whole-brain irradiation improved the symptoms due to cerebral edema. Thereafter, olaparib was started, and treatment was continued while maintaining partial response(PR).